Would you recommend the following article to a politician, an athlete, a business executive, or a scientist?

Genelabs plunges on failed study BOSTON (CBS.MW) -- Shares of Genelabs Technologies Inc. plummeted early Tuesday after the biotechnology firm announced that its lupus drug Prestara has proven ineffective in a Phase III clinical study.
